7 月 17 日,NMPA 官网显示,诺和诺德司美格鲁肽注射液的获批一项新适应症。根据公开资料和临床试验进展,Insight 数据库推测,本次获批新适应症可能为:成人 2 型糖尿病合并慢性肾脏疾病。*如需获取 2025 年更多新药获批情报,扫描文末二维码添加小音,即可免费下载。截图来自:NMPA 官网慢性肾脏病(CKD)是 2 型糖尿病的常见并发症,约 40% 的 2 型糖尿病患者会患上 CKD。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.